MorphoSys AG to Present at Two Investor Conferences in September

MARTINSRIED / MUNCHEN, GERMANY--(Marketwire - September 16, 2011) -

MorphoSys AG / MorphoSys to Present at Two Investor Conferences in September. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that management will present at two international investor conferences in September.

UBS Global Life Sciences Conference Date: September 19, 2011 at 8:30am EST (1:30pm BST, 2:30pm CEST) Venue: New York, USA Participants: Dr. Simon Moroney, CEO of MorphoSys AG Dr. Claudia Gutjahr-Loser, Head of Corporate Communications & IR Jefferies 2011 Global Healthcare Conference Date: September 27, 2011 at 9:20am BST (10:20am CEST, 4:20am EST) Venue: London, UK Participants: Dr. Simon Moroney, CEO of MorphoSys AG Dr. Claudia Gutjahr-Loser, Head of Corporate Communications & IR 

A PDF version of the Company presentation will be provided at www.morphosys.com/presentations. Links to the webcast, if available, are filed under www.morphosys.com/conference-calls.

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world’s leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol “MOR”. For further information, visit http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

MorphoSys AG Lena-Christ-Str. 48 Martinsried / Munchen Germany WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse; 

Conference Announcement: http://hugin.info/130295/R/1546958/474706.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1546958]